DiaMedica Therapeutics Inc. (DMAC) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil slips on weaker demand outlook and higher US stocks amid supply disruptions
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results
August 14, 2023 4:13 PM EDTConference Call and Webcast August 15 at 8:00 am Eastern Time / 7:00 am Central Time
Company Resumes ReMEDy2 Clinical Trial after Clinical Hold Lifted Company Completed a $37.5M At-The-Market Private Placement, Cash Runway Into 2026 Company Completed an Additional Safety Cohort of ACEi Patients in its Phase 1C Healthy Volunteer StudyMINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update... More
